In the phase II RUCAPANC trial enrolling 19 BRCA1/2-mut pancreatic cancer patients (with three of those harboring a somatic BRCA mutation), rucaparib led to response in 15.8% (n = 3, 2 PR, 1 CR) of patients (83). The gene discussed is BRCA1; the disease is pancreatic neoplasm.